Navigation Links
Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
Date:6/25/2010

"A positive opinion for VPRIV in the EU, earlier than expected, is very good news, particularly as we have been working with physicians in 22 countries for almost a year to treat patients with type 1 Gaucher disease through early access programs," said Sylvie Gregoire, President, Shire Human Genetic Therapies. "We look forward to our ongoing collaboration with these physicians and the Gaucher community at large as we enter the final stages of the approval process in Europe."

In addition to the CHMP positive opinion, VPRIV has received orphan drug designation from the Committee for Orphan Medical Products.

With the accelerated adoption of VPRIV worldwide, and the earlier than anticipated US approval and EU positive opinion, Shire expects continued high demand for the therapy. As a result of this, the company is now implementing a program with physicians and patients to monitor and manage requests from new patients carefully in order to ensure long-term, uninterrupted treatment with VPRIV.

Shire's VPRIV clinical development program represents the largest and most comprehensive clinical data set supporting registration for an ERT for Type 1 Gaucher disease to date.

About VPRIV(TM)

VPRIV is made using Shire's gene-activation technology, in a human cell line. The glucocerebrosidase enzyme produced has the exact human amino acid sequence and has a human glycosylation pattern.

VPRIV was approved by the U.S. Food and Drug Administration on February 26, 2010. For full US prescribing information see

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire plc Appoints Two New Board Directors
2. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
3. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
4. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
5. Shires Replenished Portfolio Drives Excellent Quarterly Performance
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Shire Supports Rare Disease Day 2010
8. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
9. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
10. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
11. New Shire Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Due to a misstatement posted by ... Adult Stem Cell Technology Center, LLC ( ASCTC ) was ... therapy research that might benefit ALS patients. Because of ... stem cell technologies and therapeutic applications, FRC listed ASCTC as ... donors who wish not to support research that requires ...
(Date:8/28/2014)... 28, 2014 Best Sanitizers, Inc., the ... alcohol-based hand sanitizer, asks food processors and food handling ... hand sanitizer they’re currently using to Best Sanitizers’ ... is critical to fighting cross-contamination and the spread of ... believes there are key criteria that make a hand ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... TALLAHASSEE, Fla. Exciting new work by a Florida ... molecular system that can take your temperature, emit white ... , And, the molecule looks like a butterfly. , ... and Biomedical Engineering in the FAMU-FSU College of Engineering, ... ago, but has continued to discover that his creation ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... DIEGO and AUSTIN, Texas, Aug. 16 DJO Incorporated,(NYSE: ... services that promote,musculoskeletal and vascular health, today reported that ... granted early termination of the,waiting period under the Hart-Scott-Rodino ... acquisition of DJO by an affiliate of,ReAble Therapeutics, Inc. ...
... Technology,s Robert Lanza, MIT,s Robert ... Langer, and Harvard,s Joseph Vacanti, WORCESTER, Mass., ... medicine, Robert Lanza, M.D.,VP Research & Scientific Development for Advanced ... at MIT,(recent recipient of the National Medal of Science), and ...
... Sales Up 49%, Pre-Tax Net Income Up 42%, ... Inc. (OTC Bulletin Board: CKGT), a vertically integrated,grower, developer, ... today filed its report on Form 10QSB and reported ... All results reported,are in U.S. dollars. The Company ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4New Edition of Definitive Resource in Tissue Engineering Released Today 2New Edition of Definitive Resource in Tissue Engineering Released Today 3China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results 2China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results 3
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
(Date:8/28/2014)... unique method for delivering compounds that could ... and AIDS may be possible, thanks to ... Sciences., A semi-soft vaginal suppository made from ... with the antiviral drug Tenofovir provides a ... the spread of sexually transmitted infections during ...
(Date:8/28/2014)... new roads will be built worldwide by 2050. Many ... where they bring an influx of destructive loggers, hunters ... has created a ,global roadmap, for prioritising road building ... demands of development and environmental protection. , The map ... natural importance of ecosystems and a ,road-benefits, layer that ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3
... Ohio Recent research that links specific pieces of ... lead the way to the prevention of viroids, pathogens ... plants. The findings and the research approach ... applications in the study of how certain viruses spread ...
... us have missed a dose of antibiotic or forgotten to ... as they are for people with HIV/AIDS a ... for the entire population. Now, a breath monitoring device ... Inc. could help prevent the emergence of drug-resistant strains of ...
... definitive critical review, scientists at Childrens Hospital & ... biological or behavioral evidence linking vitamin D deficiency ... staff scientist and Bruce N. Ames, Ph.D., senior ... conclude that there is ample biological evidence to ...
Cached Biology News:Analysis of RNA role in spreading disease advances study of damaging plant infections 2Analysis of RNA role in spreading disease advances study of damaging plant infections 3Analysis of RNA role in spreading disease advances study of damaging plant infections 4Scientists test device to track medication adherence in patients with HIV/AIDS 2Scientists test device to track medication adherence in patients with HIV/AIDS 3Vitamin D in brain function 2Vitamin D in brain function 3
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... (Cap Analog) is used for the synthesis ... vitro transcription reactions. Substitution of cap analog ... in an in vitro transcription reaction results ... into a large fraction of the transcripts. ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: